A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Pancreatic Cancer

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC)

Study Overview

• Status: Not yet recruiting
• Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
• Intervention / Treatment: Drug: HLX43 DOSE 1 (2.5 mg/kg); Drug: HLX43 DOSE 2 (3.0 mg/kg)

Detailed Description

This study is an open-label phase II clinical study to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC). In this study, eligible subjects will be randomized at 1:1 ratio, and the patients will be administered with HLX43 at different doses via intravenous infusion.

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Xianjun Yu, Dr; Phone Number: +86 13801669875; Email: yuxianjun@fudanpci.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Fully understand the study content, procedures, and potential adverse reactions before the trial, sign the informed consent form (ICF), voluntarily participate in the trial, and be able to complete the study per the protocol requirements;
2. Age ≥ 18 years, ≤75 years, at the time of signing the ICF, regardless of gender;
3. Histologically or cytologically confirmed, unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC),who has failed at least one prior line of standard systemic therapy. The prior therapy must have included a fluoropyrimidine-based or gemcitabine-based regimen;
4. At least one measurable lesion per RECIST v1.1 within 4 weeks before randomization;
5. Willing to provide archived (preferably within 2 years) or fresh tumor tissue specimens for the detection of PD-L1 expression.
6. At least 3 weeks (or 5 half-lives, whichever is shorter) since last major surgery, medical device treatment, radiotherapy (except palliative bone radiotherapy), cytotoxic chemotherapy, immunotherapy, or biological therapy; ≥2 weeks since last hormonal therapy or small molecule targeted therapy; ≥1 week since last traditional Chinese medicine treatment with anti-tumor indications or minor surgery; with treatment-related adverse events recovered to CTCAE v5.0 ≤ grade 1 (except grade 2 peripheral neuropathy and alopecia);
7. ECOG performance status 0-2 within 1 week before randomization;
8. Expected survival ≥ 3 months；
9. Adequate organ function within 1 week before randomization (no blood transfusion or colony-stimulating factors within 14 days prior to first dose)
10. Fertile participants must use ≥1 highly effective contraceptive method during the trial and for ≥6 months after last dose; females of childbearing potential must have negative pregnancy test within 7 days before enrollment.

Exclusion Criteria:

1. Histologically or cytologically confirmed as other pathological types of pancreatic cancer or containing components of other pathological differentiation;
2. Prior treatment with an antibody-drug conjugate (ADC) of topoisomerase I;
3. Received radical radiotherapy within 3 months prior to the first dose;
4. History of other malignancies within 2 years prior to randomization (except radically treated early-stage malignancies);
5. History of an adverse event that led to permanent discontinuation of prior immunotherapy, or a history of ≥ Grade 2 immune-mediated pneumonitis or immune-mediated myocarditis;
6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
7. Presence of spinal cord compression or clinically active central nervous system metastases (defined as untreated or symptomatic metastases, or those requiring corticosteroids or anticonvulsants), carcinomatous meningitis, or leptomeningeal disease;
8. History or presence of clinically significant pulmonary impairment due to concurrent lung disease, Subjects with a history of radiation pneumonitis within the past 6 months are also excluded;
9. Poorly controlled cardiovascular/cerebrovascular conditions;
10. Active systemic infections requiring IV antibiotics within 2 weeks pre-randomization;
11. Use of strong CYP2D6/CYP3A inhibitors/inducers within 2 weeks pre-randomization;
12. Systemic corticosteroid use (>10mg prednisone/day equivalent) or immunosuppressants within 2 weeks pre-randomization. Exceptions: Topical/ocular/intra-articular/nasal/inhaled steroids; short-term prophylactic use for contrast agents;
13. Active/suspected autoimmune diseases. Exceptions: Hypothyroid patients on thyroid replacement; controlled type 1 diabetes with insulin;
14. Live/attenuated vaccines within 4 weeks pre-randomization;
15. History of severe hypersensitivity to biologics/monoclonal antibodies or trial drug components;
16. Active tuberculosis;
17. Immunodeficiency disorders (HIV-positive or congenital/acquired immune deficiencies);
18. Active HBV/HCV infection or co-infection;
19. Pregnant/lactating women;
20. Undergone biliary stent placement within 7 days prior to randomization, or has unrelieved biliary or duodenal obstruction despite active treatment;
21. Suspected acute pancreatitis or a history of pancreatitis requiring clinical intervention recently;
22. Investigators' judgment of clinical/lab abnormalities or other factors making participation inappropriate.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HLX43 DOSE 1 (2.5 mg/kg); Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)	Drug: HLX43 DOSE 1 (2.5 mg/kg); HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Experimental: HLX43 DOSE 2 (3.0 mg/kg); Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)	Drug: HLX43 DOSE 2 (3.0 mg/kg); HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PFS	Defined as the time (in months) from randomization to the first confirmed and documented progressive disease or death (whichever occurs first) as assessed by INV per RECIST v1.1.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
ORR	Objective response rate (ORR) is the proportion of subjects with the best overall response being CR or PR (assessed by investigator per RECIST v1.1)	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ORR	Objective response rate (ORR) (assessed by the IRRC per RECIST v1.1)	up to 24 week
PFS	Defined as the time (in months) from randomization to the first confirmed and documented progressive disease or death (whichever occurs first) as assessed by the IRRC per RECIST v1.1.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
OS	Overall Survival	From randomization to death from any cause (up to approximately 18 months)
DOR	Duration of response (DOR) is defined as the time from first response (CR or PR) until PD (RECIST v1.1) or death due to any cause, whichever occurs first.	up to 18 months
DCR	Disease control rate (DCR) is defined as the proportion of subjects with a best overall response of CR, PR, or SD. Tumor response will be assessed by the investigator or IRRC as per RECIST v1.1.	up to 12 months
Incidence and severity of adverse events (AEs)	Adverse events (AEs), serious adverse events (SAEs), laboratory tests, vital signs, 12-lead ECG, and physical examination	time from the date of the first dose of study drug until 90 days after last dose, assessed up to 18 months

Collaborators and Investigators

• Sponsor: Shanghai Henlius Biotech

Study record dates

Study Major Dates

• Study Start (Estimated): December 29, 2025
• Primary Completion (Estimated): February 21, 2028
• Study Completion (Estimated): March 23, 2028

Study Registration Dates

• First Submitted: November 25, 2025
• First Submitted That Met QC Criteria: December 9, 2025
• First Posted (Actual): December 24, 2025

Study Record Updates

• Last Update Posted (Actual): December 24, 2025
• Last Update Submitted That Met QC Criteria: December 9, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: HLX43-PDAC201

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No